NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 421
(Total Views: 197)
Posted On: 04/20/2023 3:33:22 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expanding Portfolio with Four New Patents
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has received notifications of four new patents either awarded or allowed. In Japan, the company secured a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents. This is Lexaria’s fifth awarded patent in Japan, providing strength to its growing Japanese patent portfolio. In Australia, Lexaria has received a new patent under its Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is Lexaria’s 10th patent in Australia and its second in this patent family. In Canada, Lexaria has been advised of allowance of a new patent under its Patent Family #8: Compositions Infused With Nicotine Compounds and Methods of Use Thereof. This is Lexaria’s second patent in this family and follows a similar issuance in Australia in 2022. In the USA, Lexaria has been advised that a new patent under its Patent Family #21: Compositions and Methods for Treating Hypertension has been allowed. To be the first patent in this family, Lexaria believes this could be of particular importance related to its pursuit of utilizing DehydraTECH-CBD in relation to its expected upcoming FDA Investigational New Drug application.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has received notifications of four new patents either awarded or allowed. In Japan, the company secured a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents. This is Lexaria’s fifth awarded patent in Japan, providing strength to its growing Japanese patent portfolio. In Australia, Lexaria has received a new patent under its Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is Lexaria’s 10th patent in Australia and its second in this patent family. In Canada, Lexaria has been advised of allowance of a new patent under its Patent Family #8: Compositions Infused With Nicotine Compounds and Methods of Use Thereof. This is Lexaria’s second patent in this family and follows a similar issuance in Australia in 2022. In the USA, Lexaria has been advised that a new patent under its Patent Family #21: Compositions and Methods for Treating Hypertension has been allowed. To be the first patent in this family, Lexaria believes this could be of particular importance related to its pursuit of utilizing DehydraTECH-CBD in relation to its expected upcoming FDA Investigational New Drug application.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)